Xanadu Quantum Technologies Limited Class B Subordinate Voting Shares
TSX:XNDULive AI agent
Xanadu is a company founded in 2016, headquartered in Toronto, with over 300 employees.
Investor website: https://xanadu.ai/
About
Xanadu is a company founded in 2016, headquartered in Toronto, with over 300 employees. Its mission is to build quantum computers that are useful and available to people everywhere. The company is publicly traded on NASDAQ/TSX under the ticker symbol XNDU.
Verified company data
- Cash position
- $272.5 million
- Shares outstanding
- 304,223,024
- Fully diluted shares
- 293,655,720
- Projects
- ["Xanadu Pioneers the Use of Quantum Computers in Photodynamic Cancer Therapy Research\n\nDecember 19, 2025\n\nTORONTO, ON (December 19, 2025) - Xanadu Quantum Technologies Inc. (“Xanadu”), a leading photonic quantum computing company, today announced that it has developed a novel quantum computational framework to accelerate the discovery of next-generation photosensitizers for photodynamic cancer therapy, a targeted cancer treatment. Published as a pre-print article on arXiv, Xanadu’s new research demonstrates how fault-tolerant quantum computers can accelerate research into cutting-edge cancer treatments.\n\nPhotodynamic cancer therapy uses light-activated compounds called photosensitizers to selectively destroy tumor cells, typically resulting in less collateral damage than conventional treatments, such as chemotherapy. However, a photosensitizer’s success or failure often depends on complex properties, such as sensitivity to specific wavelengths of light and efficiency in triggering cancer cell death. Through the application of quantum simulation algorithms to four diverse photosensitizers, several of which are particularly challenging for classical simulations, Xanadu’s new research shows that quantum computers can effectively simulate the key properties needed to model and improve these treatments.\n\n“The development of effective photosensitizers is currently hampered by the high cost and runtime required for experimental synthesis and classical simulations. We believe our results position fault-tolerant quantum computing as a highly attractive solution for discovering advanced photosensitizers by modelling key physical properties,” says Christian Weedbrook, Founder and Chief Executive Officer of Xanadu.\n\nThrough this work, Xanadu provides a blueprint for an efficient, quantum-based workflow that can help identify potentially promising drug candidates. By focusing on simulating critical physical properties, such as cumulative absorption and intersystem crossing rates, Xanadu provides a way to determine, from first principles, which photosensitizer candidates could lead to highly efficient generation of reactive, cancer-killing molecules, thereby supporting the effectiveness of the photodynamic cancer treatment. In addition, the research provides estimates for the computational resources required to run these algorithms on utility-scale quantum computers and indicates potential speed and efficiency gains over classical methods.\n\nThis research serves as a foundational step toward a quantum-based workflow for drug design, with additional work planned to extend the framework to model more complex photosensitizer molecules. It provides an exciting new avenue for quantum computing to push the boundaries of drug development and cancer treatment."]
- Leadership
- Glenda Dorchak (Director, Over thirty years in operational leadership roles in the technology industry. Served as CEO and advisor of GMD Enterprises since July 2013, and held various roles at IBM Corporation.), Bill Fradin (Director, Almost 20 years of finance experience with expertise in mergers and acquisitions, private equity, and venture capital. Served as Executive Vice President of Osprey Technology Acquisition Corp. and Co-Founder of HEPCO Capital Management.), Eliot Pence (Director, Founder of Dominion Dynamics and builder of frontier defense and industrial companies. Led global growth at Anduril Industries and served as Chief Business Officer at Osmo and Cambium Biomaterials.)
Verified data last updated:
Recent filings
- News release · xndu_2026-10-19_10-10-52.pdf
- News release · xndu_2026-09-30_20-49-23.pdf
- News release · xndu_2026-09-22_20-30-27.pdf
- Non-issuer's submission to jurisdiction and appointment of agent · xndu_2026-08-31_12-48-18.pdf
- Auditors' consent letter · xndu_2026-08-28_13-46-53.pdf
- Non-issuer's submission to jurisdiction and appointment of agent · xndu_2026-08-28_13-46-22.pdf
- Non-issuer's submission to jurisdiction and appointment of agent · xndu_2026-08-28_13-45-51.pdf
- Non-issuer's submission to jurisdiction and appointment of agent · xndu_2026-08-28_13-45-20.pdf